已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.

医学 帕妥珠单抗 曲妥珠单抗 乳腺癌 内科学 临床终点 肿瘤科 新辅助治疗 代理终结点 癌症 临床试验
作者
Ulrike Nitz,Oleg Gluz,Monika Graeser,Matthias Christgen,Sherko Kuemmel,Eva-Maria Grischke,Michael Braun,Doris Augustin,Jochem Potenberg,Katja Krauss,Claudia Schumacher,Helmut Forstbauer,Toralf Reimer,Andrea Stefek,Hans Holger Fischer,Enrico Pelz,Christine Zu Eulenburg,Ronald Kates,Rachel Wuerstlein,Hans Heinrich Kreipe,Nadia Harbeck
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:23 (5): 625-635
标识
DOI:10.1016/s1470-2045(22)00159-0
摘要

Several de-escalation neoadjuvant strategies have been investigated to reduce the use of chemotherapy in HER2-positive early breast cancer using pathological complete response as a surrogate endpoint; there are few survival data from these trials. Here, we report 5-year survival data in the WSG-ADAPT-HER2+/HR- trial and address the effect of pathological complete response, early therapy response, and molecular subtype.WSG-ASAPT-HER2+/HR-, a part of the ADAPT umbrella trial performed in patients with different subtypes of early breast cancer, was an investigator-initiated, multicentre, open-label, randomised, phase 2 trial done at 40 Breast Cancer Centres in Germany. Eligible patients were aged 18 years or older with histologically confirmed, unilateral, primary invasive, non-inflammatory early breast cancer, hormone receptor-negative and HER2-positive status, and an Eastern Cooperative Oncology Group performance status of 0 or 1 or a Karnofsky performance status of at least 80%. Patients were randomly assigned (5:2, block size 21, stratified by centre and clinical nodal status) to 12 weeks of either trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks) plus pertuzumab (840 mg loading dose, then 420 mg every 3 weeks) or trastuzumab plus pertuzumab plus paclitaxel (80 mg/m2 weekly); all drugs were administered intravenously. The primary objective of the trial was to compare the number of patients with a pathological complete response at surgery (ie, no invasive tumour cells in breast and lymph nodes [ypT0/is ypN0], the primary endpoint) in early responders (ie, low cellularity or Ki67 decrease ≥30% after 3 weeks) in the trastuzumab plus pertuzumab group versus all patients (irrespective of an early response) in the trastuzumab plus pertuzumab plus paclitaxel group. Non-inferiority was defined as a pathological complete response no worse than 23% lower in the early-responder proportion of patients in the trastuzumab plus pertuzumab group than in the entire trastuzumab plus pertuzumab plus paclitaxel group. The primary endpoint has been reported previously. Additionally, the primary objective of the ADAPT umbrella trial was the evaluation of the effect of pathological complete response on invasive disease-free survival. At investigator's discretion, further chemotherapy could be omitted in patients with a pathological complete response. Secondary survival endpoints were 5-year invasive disease-free survival, relapse-free survival, locoregional relapse-free survival, distant disease-free survival, and overall survival. The effect of pathological complete response on survival was estimated by Cox regression analysis. All analyses are reported in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01817452, and is closed to recruitment.Between March 3, 2014, and Oct 6, 2015, 134 patients were recruited and randomly assigned to treatment, 92 to trastuzumab plus pertuzumab and 42 to trastuzumab plus pertuzumab plus paclitaxel. Median follow-up in survivors was 59·9 months (IQR 53·4-61·4). There were no significant differences between the treatment groups in invasive disease-free survival, relapse-free survival, locoregional relapse-free survival, distant disease-free survival, and overall survival. In the trastuzumab plus pertuzumab plus paclitaxel group and in the trastuzumab plus pertuzumab group, the proportions of patients achieving 5-year survival respectively were 98% (95% CI 84-100) and 87% (78-93) for invasive disease-free survival (hazard ratio [HR] 0·32, 95% CI 0·07-1·49; p=0·15); 98% (95% CI 84-100) and 89% (79-94) for relapse-free survival (HR 0·41, 95% CI 0·09-1·91; p=0·25); 100% (95% CI not estimable) and 95% (88-98) for locoregional relapse-free survival (HR 0·41, 95% CI 0·05-3·75; p=0·43); 98% (95% CI 84-100) and 92% (83-96) for distant disease-free survival (HR 0·35, 95% CI 0·04-3·12; p=0·36), and 98% (95% CI 84-100) and 94% (86-97) for overall survival (HR 0·41, 95% CI 0·05-3·63; p=0·43). Pathological complete response was associated with improved invasive disease-free survival (HR 0·14, 95% CI 0·03-0·64; p=0·011). Two invasive disease-free survival events occurred after a pathological complete response (one in each treatment group).The WSG-ADAPT-HER2+/HR- trial showed good survival rates in patients with a pathological complete response after de-escalated 12-week trastuzumab plus pertuzumab with or without weekly paclitaxel. Omission of further chemotherapy did not affect invasive disease-free survival in patients with a pathological complete response. 12 weeks of weekly paclitaxel plus dual HER2 blockade could be an efficacious de-escalated neoadjuvant regimen in patients with hormone receptor-negative, HER2-positive early breast cancer with high pathological complete response rates and good 5-year outcomes. Further trials of this approach are ongoing.Roche, Bayer.For the German translation of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刻苦的若云完成签到 ,获得积分10
2秒前
雪满头的应助被che采纳,获得10
3秒前
shoyoyo完成签到 ,获得积分10
6秒前
aimynora完成签到 ,获得积分10
6秒前
万寿宫人发布了新的文献求助10
7秒前
木雨完成签到 ,获得积分10
7秒前
omo完成签到 ,获得积分10
9秒前
12秒前
ZZY完成签到,获得积分10
16秒前
贪玩的梦容完成签到,获得积分10
16秒前
刻苦灯泡发布了新的文献求助10
17秒前
科研通AI6.3的应助被dpcrel采纳,获得10
19秒前
lin完成签到,获得积分10
19秒前
风趣青筠完成签到,获得积分10
20秒前
逮劳完成签到 ,获得积分10
23秒前
OK发布了新的文献求助10
29秒前
Newky完成签到 ,获得积分10
30秒前
33秒前
33秒前
予若完成签到,获得积分10
33秒前
zdc233发布了新的文献求助10
37秒前
科研通AI6.3的应助被hehe采纳,获得10
37秒前
37秒前
睡个好觉完成签到 ,获得积分10
38秒前
雨霖铃完成签到,获得积分10
38秒前
了了完成签到,获得积分10
39秒前
hyyyyyyy完成签到,获得积分10
43秒前
余韵完成签到 ,获得积分10
45秒前
山东老铁完成签到,获得积分10
45秒前
所所的应助被Gotye0829采纳,获得10
46秒前
47秒前
kadqcc完成签到 ,获得积分10
48秒前
117完成签到 ,获得积分10
48秒前
开心每一天完成签到,获得积分10
49秒前
咩咩咩咩吗完成签到,获得积分10
51秒前
刻苦灯泡完成签到 ,获得积分10
54秒前
MiaWood362发布了新的文献求助10
58秒前
1分钟前
1分钟前
佳佳完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194894
求助须知:如何正确求助?哪些是违规求助? 9580685
关于积分的说明 21872290
捐赠科研通 7794613
什么是DOI,文献DOI怎么找? 3437801
关于科研通互助平台的介绍 2561143
邀请新用户注册赠送积分活动 2484511